New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2013
07:16 EDTECYT, SGENEndocyte added to Top Picks list; Seattle Genetics removed at Credit Suisse
Credit Suisse added Endocyte to the Top Picks list based on vintafolide regulatory and clinical events over the next 12 months, a strong cash position, and asset ownership, among other reasons.
News For ECYT;SGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
12:32 EDTSGENAnalysts differ on Seattle Genetics outlook after data
Subscribe for More Information
10:02 EDTSGEN, ECYTOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:10 EDTSGENOn The Fly: Pre-market Movers
Subscribe for More Information
08:18 EDTSGENSeattle Genetics downgraded at BofA/Merrill
As previously reported, BofA/Merrill downgraded Seattle Genetics to Underperform from Neutral. The firm said AETHERA data for interim overall survival advantage was not significant and could reinforce Adcetris' role as a salvage therapy as opposed to a frontline option. Price target lowered to $34 from $40.
07:43 EDTSGENSeattle Genetics outlook still positive, says RBC Capital
Subscribe for More Information
06:16 EDTSGENSeattle Genetics downgraded to Underperform from Neutral at BofA/Merrill
05:28 EDTECYTEndocyte downgraded to Hold from Buy at Brean Capital
Brean Capital downgraded Endocyte to Hold saying it views the company's data for vintafolide as "marginal."
September 29, 2014
13:07 EDTSGENSeattle Genetics weakness a buying opportunity, says Credit Suisse
Credit Suisse said Seattle Genetics top-line AETHERA data was significantly positive for the primary endpoint and expects full results in December at ASH to provide a meaningful update. The firm would use weakness as a buying opportunity and reiterates its Outperform rating and $51 price target.
12:59 EDTSGENSeattle Genetics positive data largely as expected, says Piper Jaffray
Piper Jaffray says the Seattle Genetics' positive top-line data from the Phase III ATHERA trial of ADCETRIS for consolidation therapy in high risk Hodgkin's lymphoma patients following stem cell transplant was largely as expected. Piper sees the potential for label expansion, but keeps an Underweight rating on the stock with a $26 price target.
06:49 EDTSGENSeattle Genetics, Takeda announce positive data from Phase 3 trial of Adcetris
Seattle Genetics and Takeda Pharmaceutical announced that patients with Hodgkin lymphoma who received ADCETRIS as consolidation therapy immediately following an autologous stem cell transplantation lived significantly longer without disease progression compared to patients who received placebo. The phase 3 clinical trial, known as AETHERA, compared the use of single agent ADCETRIS to placebo in 329 patients with HL who were at risk of relapse. ADCETRIS is an antibody-drug conjugate directed to CD30, a defining marker of classical HL. The AETHERA trial met its primary endpoint with ADCETRIS treatment resulting in a statistically significant improvement in progression-free survival versus placebo as assessed by an independent central review committee, which equates to a 75% improvement in PFS. PFS was assessed after a minimum of two years post initiation of treatment for all study patients. A pre-specified interim analysis of overall survival showed no statistically significant difference between the treatment arms. Patients on both study arms with progression of HL received a variety of subsequent therapies. Notably, most patients on the placebo arm received ADCETRIS after progression. A further analysis of overall survival is planned in 2016.
06:27 EDTECYTEndocyte to host conference call
Subscribe for More Information
05:47 EDTSGENSeattle Genetics to host conference call
Subscribe for More Information
September 28, 2014
14:12 EDTECYTEndocyte says Phase 2b TARGET trial results show improved survival
Endocyte announced that the small molecule drug conjugate, SMDC, vintafolide in combination with docetaxel extended overall survival for patients with folate receptor positive recurrent non-small cell lung cancer, NSCLC, compared to patients receiving monotherapy docetaxel in its TARGET Phase 2b clinical trial. The late-breaking TARGET trial data will be presented today at the European Society for Medical Oncology Congress, ESMO, by Rohit Lal, M.D., consultant medical oncologist at Guys and St Thomas' Hospital and an Honorary Consultant Medical Oncologist for Kings College Hospital, London.
September 26, 2014
17:59 EDTSGENSeattle Genetics up nearly 4% after hours after setting date for ADCETRIS data
September 24, 2014
09:07 EDTSGENSeattle Genetics reports additional data from Phase 1 trial of ADCETRIS
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use